Bayberry Pharmaceuticals

What Bayberry Pharmaceuticals does

Bayberry Pharmaceuticals Pvt. Ltd. is a Pune, India-based pharmaceutical manufacturer founded in 2003 that produces a broad portfolio spanning allopathic, ayurvedic, nutraceutical, cosmetic, and veterinary products. The company operates a WHO-GMP certified manufacturing facility in Baddi, Himachal Pradesh, producing over 1,000 products including 300+ exclusive formulations across three divisions: Bayberry Division (human pharma), Bayberry Vet (animal health), and Genus Myrica (consumer/cosmetics). The underlying capability is regulated small-molecule and traditional formulation manufacturing supported by export-grade documentation.

The company makes money through three channels: own-brand product sales across its five categories, third-party contract manufacturing (TPM) for other pharmaceutical companies, and a portfolio of international services that include drug registrations, CTD preparation, cold chain logistics, named-patient medicine supply, and government tender participation. Its commercial footprint spans 15+ countries, with 9 new markets added in 2024, indicating an active export push alongside domestic distribution.

The company serves hospitals, retail pharmacies, veterinary practitioners, pharmaceutical companies (TPM clients), government health systems, and international patients seeking named-patient access. The combination of multiple drug categories, three operating divisions, and a service-based international layer diversifies revenue but adds operational complexity for a sub-50-employee organization.

Name

Bayberry Pharmaceuticals

Legal name

Bayberry Pharmaceuticals Pvt. Ltd.

Website

https://bayberry.co.in

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

Bayberry Pharmaceuticals is a Pune-based manufacturer of allopathic, ayurvedic, nutraceutical, cosmetic, and veterinary products from a WHO-GMP certified facility in Baddi. It serves domestic hospitals, pharmacies, and government tenders, plus international markets via TPM, drug registration, and named-patient services across 15+ countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

akta.pro secondary industries

Veterinary Pharmaceutical Wholesalers & Distributors (HLAMAIAA), Specialty Pharmacy & Biologics Distribution (CRAOAHAD)

Keywords

• Pharmaceutical manufacturing
• Generic medicines export
• Third party manufacturing
• Veterinary pharmaceuticals
• Nutraceutical formulations

Headquarters

HQ city

Pune

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: Sale of proprietary pharmaceutical formulations across Allopathic, Ayurvedic, Nutraceuticals, Cosmetics and Veterinary segments under brand names including Bayberry Division, Bayberry Vet, and Genus Myrica. Products include antibiotics, anti-inflammatory, cardiovascular, antidiabetic, hepatoprotective, and veterinary health supplements. Sales are conducted domestically in India and internationally across Africa, Asia, and other global markets.
2. Contract Manufacturing: Third-party manufacturing (TPM) services providing tailored pharmaceutical manufacturing solutions to pharmaceutical companies. Services cover formulation development, large-scale production, regulatory compliance, and quality assurance. Over a decade of expertise in contract manufacturing for leading pharma brands.
3. International Sourcing & Supply: Global sourcing and supply of pharmaceutical products including globally sourced international medicines, generic sourcing for patent drugs, cold chain logistics for temperature-sensitive products, named patient medicine procurement, regulatory services, and government tender quotes. Revenue derived from markups on sourced products and logistics fees.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels3 records

Core offering

Bayberry Pharmaceuticals manufactures and exports a portfolio of 1,000+ pharmaceutical products across Allopathic, Ayurvedic, Nutraceuticals, Cosmetics, and Veterinary formulations from its WHO-GMP certified facility. It operates through three marketing divisions (Bayberry Division, Bayberry Vet, Genus Myrica) and provides third-party contract manufacturing, international drug registration, cold chain logistics, and named patient medicine procurement services to hospitals, pharmacies, and pharmaceutical companies in over 15 countries.

Product overview

Bayberry Pharmaceuticals operates as a pharmaceutical company offering 1,000+ products across Allopathic, Ayurvedic, Nutraceuticals, Cosmetics, and Veterinary formulations through multiple divisions. The core offering includes the Bayberry Division (300+ exclusive formulations covering antibiotics, anti-inflammatory, analgesics, anti-ulcerants, antioxidants, and injectables), the Genus Myrica division (cardiac and antidiabetic medications), and Bayberry Vet (veterinary healthcare products). The company provides comprehensive services including international services (drug registrations, cold chain logistics, contract manufacturing, named patient medicine), and third-party manufacturing services through WHO-GMP certified facilities.

Differentiator

Problem solved

Functional benefit

Brands

• Bayberry Division: A diversified portfolio of 300+ exclusive formulations in various healthcare segments including antibiotics, anti-inflammatory, anti-ulcerants, and more.
• Bayberry Vet
• Genus Myrica

Products and services

• Bayberry Division A diversified portfolio of 300+ exclusive pharmaceutical formulations covering antibiotics, anti-inflammatory, analgesics, anti-ulcerants, antioxidants, vitamins, and injectables, marketed to hospitals, pharmacies, and healthcare institutions in India.
• Bayberry Vet Veterinary medications and healthcare products formulated for animal treatment and well-being, including nutritional supplements (Lycpro, Nutra Calci), liver tonics (BerryLiv), growth promoters (Berrygrow-V), laxatives (Berrylax-V), and fertility products (Berryfert-V, Utraberry-V) for livestock and poultry.
• Genus Myrica Cardiac and antidiabetic medications including Glimrica (Metformin + Glimepiride), Jusvog (Metformin + Glimepiride + Voglibose), Jusglip met, and Savtel (Telmisartan) for managing heart-related conditions and diabetes control.
• Third Party Manufacturing Services Contract manufacturing services for pharmaceutical companies offering formulation development through large-scale production with WHO-GMP certified facilities. The company manufactures customized formulations for leading pharma brands under their own brand names.
• International Services Comprehensive international business services including drug registrations and CTDs, globally sourced international medicines, government tender quotes, cold chain logistics for temperature-sensitive products, generic sourcing for patent drugs, and named patient medicine procurement.
• COPP List Products Portfolio of pharmaceutical products holding Certificate of Pharmaceutical Product (COPP) certifications for international regulatory compliance, including Swifty Tablets (Glucosamine), Aceclomag-100 (Aceclofenac), Azimor (Azithromycin), Exeed-500 (Metformin), 50-AT (Atenolol), and Megamol (Paracetamol).

Quantifiable outcome

• 100+ products portfolio across multiple therapeutic categories
• +2 more outcomes

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators6 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Caplin Point Laboratories: Mid-sized Indian pharma focused on emerging markets (Africa, Latin America), with branded generics and contract manufacturing. Closest peer in terms of international distribution profile, target geographies, and product mix.
• Ipca Laboratories: Indian pharma with strong API and formulation exports spanning 100+ countries; comparable in international sales infrastructure and generics portfolio.
• Unichem Laboratories: Indian pharma manufacturer with API and finished dosage form presence across regulated and semi-regulated markets; comparable in product breadth and export orientation.
• Hetero Drugs: Indian pharma with strong global presence in generics, APIs, and biosimilars; comparable in international distribution across emerging markets and formulation breadth.
• Emcure Pharmaceuticals: Indian pharma manufacturer with significant international presence and contract manufacturing capabilities; comparable in branded-generics + TPM business model.
• Ajanta Pharma: Indian generics manufacturer with substantial branded-generics franchise in Africa and Asia; comparable in international GTM motion and emerging-market presence.
• Akums Drugs & Pharmaceuticals: India's largest contract manufacturer of pharmaceutical formulations, offering end-to-end manufacturing services; very direct comparable in TPM (third-party manufacturing) services and dosage-form portfolio.
• FDC Limited: Indian pharma with diversified portfolio across allopathic, Ayurvedic, and nutraceutical formulations; comparable in product breadth and domestic+international distribution model.

Broad incumbents

• Aurobindo Pharma: One of India's largest generic manufacturers with extensive global footprint; comparable end-markets and product categories, but far larger scale and broader portfolio.
• Cipla: India's largest pharma exporter with broad respiratory, anti-retroviral, and chronic-disease portfolio across 80+ countries; an established incumbent in many of the same emerging markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/bayberryltd

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bayberry Pharmaceuticals